INTRODUCTION: UNIQUE FEATURES OF CANCER THERAPEUTIC DEVELOPMENT
In Japan, cancer has been the leading cause of death since 1981 and is accounting for 30% of all deaths (1) . Currently, cancer is the most significant health problem facing the Japanese people. The recent 5-year survival rate for all cancers in Japan is still only 54%, and approximately half of cancer patients die within 5 years after their diagnosis (2) . The development of anticancer therapies continues to pose a significant challenge.
Some types of cancer are curable with single-modality treatment, including surgery, radiotherapy or chemotherapy, e.g. surgery for early gastrointestinal cancer, radiotherapy for early head and neck cancer, and chemotherapy for child leukemia. However, most of the cancer patients need combined modality (multimodal) treatment for cure or for prolongation of survival, including therapies such as chemoradiation, adjuvant chemotherapy or radiotherapy before or after surgery. Advancement in chemotherapy can be achieved partly by the industry-sponsored clinical trials with the purpose of obtaining marketing approval of new anticancer agents (called 'Chi-ken' in Japanese). However, the development of combined modality treatments is not generally sponsored by pharmaceutical companies, making investigator-initiated clinical trials essential for the improvement of standard of care for cancer patients.
From an economical point of view, oncology drug development is not an attractive investment target for pharmaceutical industries. Oncology drugs account for only 2% of entire drug market in Japan. Additionally, the success rate of oncology drug development, 5%, is very low, particularly when compared with other fields such as cardiovascular disease (20%) (3) . The regulatory burden on pharmaceutical companies in the field of oncology, including, for instance, Adverse Event Reporting to regulatory agencies, is much more significant than in other fields because the oncology drugs are inevitably toxic and many reports are necessary during trials. As a logical consequence, pharmaceutical companies have been reluctant to invest in oncology drug development. In fact, so-called 'Big Pharma' in Japan had not been aggressive in anticancer drug development until very recently. All of the factors mentioned above suggest that public or academic support and leadership are necessary to improve the standard treatment of cancer patients. Therefore, publicly funded clinical trials play a vital role in answering clinical questions that are important to patients but that are unlikely to be prioritized by industry. Examples include head-to-head comparisons of different drugs from different companies, evaluation of combination chemotherapy with drugs from different companies, trials for rare diseases, assessment of multimodality therapies and determination of optimal treatment durations and doses (4) .
In the USA, oncology drug development has been directed by the National Cancer Institute (NCI), a governmental agency, since the mid-1950s (4), as the NCI was solely responsible for the technology involved in anticancer drug development following the Second World War. The NCI established the Clinical Trials Cooperative Group Program to support cooperative groups in 1955 in their testing of the new anticancer agents developed by the NCI. For over five decades, the NCI has demonstrated strong leadership in cancer therapeutic development within the USA, not only with drugs but also with other modality treatments. One of its activities has been to support cooperative oncology groups. Although the proportion of government-sponsored Phase III cancer trials decreased in recent years compared with two decades ago (60%: 1975 -84), one-third of trials are still sponsored by the government (31%: 1995 -2004), whereas industry-sponsored Phase III trials increased to 57% (1995 -2004 ) from 4% (1975-84) (5) . Thus, in the USA, it is the government, specifically the NCI, that is the major sponsor of cancer clinical trials. On the contrary, in Japan, there has been no counterpart to the NCI, and it has therefore lagged 30 -40 years behind the USA in terms of cancer therapeutic development.
HISTORY OF THE US COOPERATIVE GROUPS
Understanding the history of cancer therapeutic development in the USA is of value, as it would inform us on how best to make up the delay described above. The first cancer-related randomized cooperative clinical trial was for acute leukemia (6) (7) . The initial aim of cooperative groups was to test new anticancer agents developed by the NCI, with their focus expanded in the mid-1960s to encompass the development of new disease-oriented combination chemotherapy regimens. Up to the early 1970s, most of patients who participated in clinical trials had advanced disease. Patients with early stage disease were included in larger numbers in the late 1970s. During the 1970s and 1980s, the emphasis of cooperative group trials was expanded again to evaluate combined modality treatments. Some of the initially established cooperative groups were small and disease-specific or regional, and through the 1960s and 1970s, such small groups were combined to nationwide multidisease groups (8) . There were a total of 31 cooperative groups since 1955 to date, 14 of those remaining in 1979 and 10 remaining today. By the end of the 1970s, the configuration of the cooperative groups came to resemble their current style with each having its own large statistical center staffed by newly established professionals such as biostatisticians and data managers. In 1980 -81, when the support mechanism for the Cooperative Group Program was converted from a grant to a cooperative agreement, the Cancer Therapy Evaluation Program (CTEP) in the NCI took on a considerable role in the oversight of cooperative groups, including trial concept selection, protocol review and approval, and oversight of trial operations (4) .
The NCI-sponsored cooperative groups, which are called 'Groups', are currently comprised of four main types: (i) disease-oriented groups-GOG (Gynecologic Oncology Group) and NSABP (National Surgical Adjuvant Breast and Bowel Project); (ii) groups that focus on high-technology or single-modality studies-ACOSOG (American College of Surgeons Oncology Group), ACRIN (American College of Radiology Imaging Network) and RTOG (Radiation Therapy Oncology Group); (iii) groups in which investigators focus on a particular patient population-COG (Children's Oncology Group); (iv) multimodality national groups (called the 'Big 4')-CALGB (Cancer and Leukemia Group B), ECOG (Eastern Cooperative Oncology Group), NCCTG (North Central Cancer Treatment Group) and SWOG (Southwest Oncology Group) (4). Typically, cooperative groups' statistical centers are associated with major university biostatistics departments, such as Duke University with (10) .
The group sequential approach, which is a statistical term denoting procedures for interim analyses in Phase III randomized trials, was developed in the mid-1970s and was established in the 1980s. With this currently common method, interim analyses for early termination of the study are done at a limited number of pre-specified points during the course of a clinical trial (10) . Up to the late 1970s, it was common practice to report annual or semi-annual interim outcome analyses of randomized studies to all investigators in Cooperative Groups. By the mid-1980s, demerits of this practice, which threaten the integrity of the study and reliability of the results, had became widely recognized, and dissemination of interim outcome reports became limited to a trial steering committee. Furthermore, in the 1990s under the leadership of the NCI, a data safety monitoring committee with a majority of members drawn from outside the cooperative group itself was assigned to review the interim analysis reports and to recommend whether a trial was to be continued or to be terminated early. This approach is now common worldwide (11) .
Beyond 2000, methodological advances occurred in two major areas. One is the development of study design for the evaluation of targeted drugs using biomarkers, and the other is the international collaborative study framework. The details are discussed in excellent reviews by Sargent et al. (12), Mandrekar and Sargent (13) and Trimble et al. (14) .
The situation regarding pediatric oncology group trials has many unique features when compared with the adult cancer trials. For example, 90-95% of US children with cancer participate in clinical trials, whereas only 3% of US adults with cancer participate in clinical trials (4, 9) . The scope of this manuscript is limited to the therapeutic development in adult cancer.
DEVELOPMENT OF JAPANESE COOPERATIVE GROUPS

History repeats itself
Karl Marx
The history of cancer clinical trials in Japan seems to follow that in the USA. Before the mid-1980s, there existed no investigator-initiated cancer cooperative groups as they are constituted today. Although small groups or informal consortiums conducted clinical researches on cancer therapy, most of this research consisted of retrospective studies, case series studies or industry-sponsored clinical trials. In the mid-1980, a couple of groups began investigator-initiated multiinstitutional prospective clinical trials; however, they had no organized data coordinating center with statisticians and data managers. As was the case in the USA in the 1950s, study management procedures were undertaken by clinicians and their secretaries with insufficient knowledge of biostatistics and data management. In the 1980s, Nagahiro Saijo, the second chair of the Japan Clinical Oncology Group (JCOG) and the first Japanese member of the Executive Committee of the American Society of Clinical Oncology (ASCO), along with other opinion leaders, aggressively introduced clinical trial methodology and cooperative group mechanisms being established in the USA and the Europe to the Japanese oncology community. And since around 1990, the concept and importance of clinical data management and statistical methodology in clinical trials have been recognized by the clinical oncology community thanks to tremendous efforts by Yasuo Ohashi, a leading statistician at the University of Tokyo. From the late 1980s through the early 1990s, the leaders of spontaneously forming research groups became aware of the importance of data coordinating centers that are continuously organized by statisticians and data managers, and several groups established centers capable of central patient registration and central randomization with full-time data managers. This turning point occurred in Japan at least 30 years after it took place in the USA.
Through the 1990s, the coordinating centers of such groups had been gradually organized to increase the quality and quantity of clinical trials; however, they were continuously unstable and administratively fragile, especially in their hiring practices. The governmental research funds had many limitations in hiring people, such as inability to guarantee social security and health insurance, a low upper salary limit and no commuting allowance. These restrictions posed significant hurdles to hiring new experts on clinical trials and retaining existing ones, especially data managers. Since 2000, most of the groups had established the corporate entity, i.e. non-profit organizations, within the group or by the group as a whole. To date, each major cooperative group in Japan has its own corporate entity and hires peoples in a stable manner even though the stability of administrations is insufficient and varies in their affiliation or parent organization by groups.
Methodological advancement has been accomplished in cooperative groups in Japan by introducing US and European approaches to managing multicenter cancer clinical trials. It is currently thought that Japan lags behind Western countries by 10 years in terms of methodological development. For example, interim analysis reports had been opened to steering committees in Japan annually or semi-annually before the mid-1990s; however, excluding participating investigators from a data and safety monitoring committee review as is the current worldwide standard occurred only in the late 1990s. At this point, most of the statistical methods used in Japanese cooperative groups are identical to those used by their US and European counterparts.
HISTORY OF ORGANIZING JCOG: AN EXAMPLE
Ontogeny recapitulates phylogeny Ernst Heinrich Philipp August Haeckel
Recapitulation theory holds that the growth and development of an individual organism copies the evolutionary history of the species (Wikipedia). The developmental process of an individual cooperative group seems to copy the history of the methodological advancement of the entire clinical trials enterprise. Therefore, reviewing the history of a specific cooperative group and/or data coordinating center is considered to be of help in understanding the principle of clinical trials as well as methodological and organizational advancement. The history of JCOG is one example of the formation of a cooperative group structure and coordinating center, and it can be used a model by an individual who desires to establish his or her own clinical trial organization.
PIONEERING DAYS AND FORMING DISEASE-ORIENTED SUBGROUPS
The initial research grant forming the basis of JCOG was secured in 1978 (15) The LCSG had two subgroups, East Japan LCSG (EJ-LCSG) and West Japan LCSG (WJ-LCSG), with the latter developing eventually into the current West Japan Oncology Group later. Each disease-oriented subgroup produced its own study protocol, conducted the study, analyzed data and published results; however, for the most part, these groups performed these activities independently from one another and there was no peer-review system encompassing the research group as a whole.
ORGANIZING OF COMMITTEES
Since 1988, the grant project was chaired by Masanori Shimoyama with a different title-'A study on the Multidisciplinary Treatment for Solid Cancer'. In 1985, under the leadership of Shimoyama, the investigators established the Constitutions and Bylaws for research activities, two core committees, the Clinical Trials Review Committee (CTRC, current Protocol Review Committee) and the Independent Monitoring Committee (IMC, current Data and Safety Monitoring Committee), and the Scientific and Ethical Guidelines for this grant-based research group. Since then, all research protocols have been reviewed and approved by the CTRC before being submitted to the institutional review board of each participating institution, and all ongoing studies have been monitored through the review of monitoring reports every 6 months by the IMC. Because the members of these two core committees consisted of the chairpersons of each subgroup or the key investigators within subgroups, these committees were not 'independent'; however, this peer-review system has been working well to improve the quality of the studies from scientific and ethical perspectives over the past two decades. The joint committee meetings by the CTRC and the IMC were held semi-annually and functioned in a decision-making capacity regarding all research activity. The joint committee was named the Steering Committee in 1987 and began meeting every 3 months, then was renamed the Executive Committee in 2000.
NAMING OF JCOG AND ESTABLISHMENT OF JCOG STATISTICAL CENTER
Before 1989, study protocols and trial data had been managed by investigators themselves (physicians or surgeons) and their secretaries. A small statistics section was set up in 1989 by Shimoyama within the National Cancer Center Hospital, and the study data were gathered into this statistics section at that time. In 1990, the grant-based research group was named the JCOG by the Steering Committee, and the statistical section was named the JCOG Statistical Center. The first JCOG Chair was Masanori Shimoyama. The subgroup structure has remained the same since. The current organizational structure is shown in Fig. 1 and the list of the subgroups and their chairpersons are shown in Table 1 .
The JCOG Statistical Center was relocated to the National Cancer Center Research Institute East, Kashiwa, Chiba, between 1995 and 1996. The Director of the Statistical Center at that time had been Shoichiro Tsugane, Chief of the Epidemiology and Biostatistics Division. In these early days, human resources were quite limited. Three to four staff members including the Director (who was not affiliated fulltime) were assigned to JCOG. The research associates and secretaries with time wages managed all trial-related jobs, such as patient registration including randomization, collecting case report forms, entering data into the database, processing semi-annual monitoring reports and roster management, for more than 30 ongoing trials and around 20 trials in follow-up. As a logical consequence, data quality and reporting of problems and safety issues to investigators was far from satisfactory.
REORGANIZING JCOG STATISTICAL CENTER INTO JCOG DATA CENTER
The Statistical Center was relocated again to the National Cancer Center Research Institute, Tsukiji, Tokyo, in 1996 and came under the direction of by Naohito Yamaguchi, Chief of the Cancer Information and Epidemiology Division. Kaoru Abe, the President of National Cancer Center at that time assigned Haruhiko Fukuda to reorganize the Statistical Center. At the time of relocation to Tsukiji, the JCOG Statistical Center managed 37 trials open for accrual and 22 trials in follow-up. Reorganization was started with the separation of the Data Management and Statistics sections as well as specification of shared responsibilities. In the early days, the data management section was composed of three data managers and an assistant, and the statistics section was composed of six staff members (statisticians and epidemiologists) in the Cancer Information and Epidemiology Division, each assigned part-time to one or two subgroups. Reorganizing efforts included prohibiting the registration of ineligible patients, reminding site investigators about unsubmitted case report forms, querying missing data and logical inconsistency, changing the language of reports from English to Japanese and compiling list of ineligible cases, protocol deviations and serious adverse events along with the names of relevant institutions. This type of feedback to the site investigators was believed to be critical in improving and maintaining the quality of data and study management, which would in turn help ensure the scientific integrity of trial results and minimize the risk of enrolled patients. The JCOG Statistical Center was renamed the JCOG Data Center in 1998, with the intent of spreading understanding of the importance of data management. In fact, the workload in data coordinating centers is much greater in data management works than in statistical jobs, not only in JCOG but also in cooperative groups worldwide. Several revisions in statistical methodology were also conducted during this period. No formal adjustment for multiplicity had been performed in the interim analysis of Phase III randomized trials before 1996, and the alpha spending function method with O'Brien and Fleming boundary (16) was introduced as a de facto standard in 1997. The adjustment based on the Southwest Oncology Group method (11) was also allowed. The formal analysis plan documents began to be processed by a statistician assigned to each subgroup prior to performing the interim analysis.
The first-generation database system, the JCOG DB system, in the Statistical Center was constructed using relational database software system G-BASE (Richo Co., Ltd). This was done as part of a Grant-in-Aid for Basic Research from the Science and Technology Agency between 1991 and 1993 (17) . The maintenance and reform of the database system was supported afterward by a Grant-in-Aid for Second Term Comprehensive 10-year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare. The first-generation JCOGDB system used UNIX as its operating system and was highly standardized across all diseases and treatment modalities. All tables could be processed and printed out in the same styles across studies; however, Japanese word-processing functionality was quite limited in those days and the system could not efficiently handle Japanese characters. These limitations resulted in difficulties with detailed reporting and feedback of problems to the investigators. The first-generation system was replaced between 1997 and 1999 by a second-generation JCOGDB system designed and constructed by customizing EDMS, a commercial clinical data management system software package by EPS Co., Ltd. The JCOG Data Center is currently using this second DB system and makes continued efforts to maintain and improve it via revisions and updates. Since the system enabled web-based patient registration in 2009, all trials initiated since 2010 are capable of enrolling subjects in this way.
The efforts mentioned above were performed in parallel with increasing the number of staff in data management and in other sections that were established one by one. The JCOG Data Center was composed of 10 members in 1998. The Computing Section, which administers hardware, software and computer networks, was created in 1998, whereas the Medical Section (currently, the Study Coordinating Section in the Operations Office) which supports drafting of protocols and publications was set up in 2002. In 2006, the Data Center and the Committee Office were reorganized into four Data Center sections, namely Data Management, Statistics, Computing Sections and the Office of the Director (general affairs, accounting, labor management, roster management, education and project management), and two sections in the Operations Office, the Study Coordinating Section and the Quality Assurance Section (audit, DSMC office).
COLLABORATION WITH THE SOCIETY OF JAPANESE PHARMACOPOEIA AND ESTABLISHMENT OF NPO-CORE
Because the number of employees in the National Cancer Center was limited by governmental regulations, the establishment of an organization, such as data coordinating center, composed of newly recognized experts was quite difficult. Persons who intended to found such organizations (including but not limited to the JCOG) were forced to seek pathways that did not create new sections within the National Centers. 
EXPANSION OF QUALITY CONTROL AND QUALITY ASSURANCE
Adverse event reporting is extremely important in reducing risk to patients enrolled in clinical trials, especially in multicenter cancer clinical trials. 'Expected' adverse events, which are defined as being described in the protocol or in the package insert, are the adverse events that the participating investigators know how to treat. Conversely, the investigators may not know how to treat patients when 'unexpected' adverse events arise, and sharing information about such adverse events among investigators would be of help in reducing patient risk. In single-institution trials, sharing such information should be done easily and spontaneously during routine clinical practice and via non-document-based communication; however, in multicenter clinical trials, such information can be shared only by exchanging documents. Thus, the information regarding an unexpected adverse event that occurs at a specific participating site should be shared among investigators in a timely manner to most effectively minimize patient risk. The first guideline for Adverse Event Reporting in JCOG was formalized in 1985 when the IMC was organized. However, there were very few adverse event reports submitted to the IMC in compliance with the guidelines until 1996. The number of adverse event reports increased from less than 10 to more than 30 per year between 1997 and 2000, when the current style of monitoring reports and the site visit auditing system were established. Minimizing risk to enrolled patients cannot be realized in the absence of a functional quality control system. (19) . The site visits have been performed on a monthly basis, usually totaling 10 visits per year. A 3-year auditing cycle is used, but only one-fourth to one-third of participating hospitals in JCOG have been audited during each cycle due to the insufficient human resources. The current cycle began in January 2009, and the frequency and total number of site visit will hopefully grow within this cycle or the next as a result of increasing the number of staff.
A protocol manual was drafted by JCOG in 1999 and formalized in 2001 for the streamlining of protocol development and for increasing the scientific quality of protocol documents. This provides a standardized chapter structure, instructions on how to write the protocol sections, and template documents required by JCOG policies and being compliant with the ethical guidelines. Streamlining of protocol development has been one of the major concerns not only in JCOG but also in the Western cooperative groups. Dilts et al. reported that median calendar days to activate a Phase III trial are 784 in CALGB (20) and 808 in ECOG (21) . According to the preliminary data analysis in JCOG, the median days to activate all JCOG protocols that were approved between 2000 and 2009 were 565. Detailed data analyses and the protocol streamlining project within JCOG are ongoing. The project includes making chapter structure of 'Background' identical between the protocol concept and full protocol, bringing transparency to the progress of protocol drafting for all JCOG investigators via a members-only site in the JCOG website monthly. It also involves establishing the new position of a protocol manger, a non-physician writing professional who supports physician protocol coordinators, and acts as a project manager and a time-keeper in protocol drafting.
THE OTHER COOPERATIVE GROUPS IN JAPAN
A brief introduction to the other cancer cooperative groups is given here. The Japanese cooperative groups, that two or more their Phase III trials are registered at the UMIN Clinical Trials Registry (http://www.umin.ac.jp/ctr/index-j. htm) as of March 2010 and group information is available at their websites, are nominated. The material in this section comes mainly from group websites, supplemented by personal communication. . N-SASBC has also focused on the health outcome research including patient-reported quality-of-life assessment. Japan contains many research groups besides those listed above that are domestic and/or specific to single diseases; however, their number and organizational structure are unknown because the country does not have a system that oversees cooperative groups.
MULTIDISEASE GROUPS
RESTRUCTURING OF THE CLINICAL TRIALS ENTERPRISE IN THE USA
The clinical trial system in the USA seems highly developed in comparison with that in Japan; however, the US Cooperative Group enterprise has been undergoing restructure since 2005 after its initial 50 years of existence. Although the US Cooperative Groups are recognized as having made great contributions to the field of cancer therapeutics over the past five decades, many stakeholders in the clinical oncology community have come to believe that the cooperative group system is increasingly inefficient, marked
